Printer Friendly

LIFE TECHNOLOGIES INC. ACQUIRES ASSETS OF RESEARCH PRODUCTS DIVISION OF TELIOS PHARMACEUTICALS INC.

LIFE TECHNOLOGIES INC. ACQUIRES ASSETS OF RESEARCH PRODUCTS DIVISION
 OF TELIOS PHARMACEUTICALS INC.
 SAN DIEGO, Calif., and GAITHERSBURG, Md., Oct. 15 /PRNewswire/ -- Life Technologies Inc. (NASDAQ: LTEK) and Telios Pharmaceuticals Inc. (NASDAQ: TLIO) today announced that Life Technologies has acquired certain assets from Telios Pharmaceuticals which were used in its manufacture and sale of research products. The purchase price is $1.3 million.
 Life Technologies has acquired exclusive rights to sell Telios' extracellular matrix research reagents for research purposes, but not for any diagnostic or therapeutic use. The acquired assets include technology licenses, a right of first refusal for new research products, customer lists, inventory and certain manufacturing assets. Telios' sales of research products for the nine months ended Sept. 30, 1992, were $817,000.
 Dr. J. Stark Thompson, president and chief executive officer of Life Technologies Inc., stated, "Through this acquisition, we have strengthened our strategic standing in the cellular biochemistry markets and look forward to expanding these markets in the future. This product line acquisition is representative of our commitment to aggressive growth and development of our business." The products will be sold under the GIBCO BRL label.
 Dr. Robert J. Erickson, president and chief executive officer of Telios, said, "We decided to sell these assets so that we can strategically focus our human and financial resources on the development of therapeutic products. We are pleased that we were able to sell these assets to Life Technologies, a company with a tradition of providing high quality extracellular matrix research reagents and excellent technical service to their customers."
 Life Technologies Inc. develops, manufactures and supplies more than 2,000 products used principally in life sciences research and commercial manufacture of genetically engineered products. The company is a leading supplier of sera and other cell growth media, as well as enzymes and other biological products necessary for recombinant DNA procedures.
 Telios is developing a new class of therapeutic products based upon research into the role of the extracellular matrix. The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases, cardiovascular diseases and osteoporosis.
 -0- 10/15/92
 /CONTACT: Audrey D. Keane, director of Corporate Development of Telios Pharmaceuticals, 619-622-2615; or Joseph C. Stokes Jr., VP Finance, or Stuart Hepburn, Ph.D., director of Corporate Development, 301-840-8000, of Life Technologies/
 (LTEK TLIO) CO: Life Technologies Inc.; Telios Pharmaceuticals Inc. ST: California IN: MTC SU: TNM


JB-KJ -- LA003 -- 0650 10/15/92 16:49 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 15, 1992
Words:416
Previous Article:FIRST AMERICAN EARNINGS UP FOR SEVENTH CONSECUTIVE QUARTER
Next Article:ALLIED GROUP DECLARES REGULAR DIVIDEND
Topics:


Related Articles
TELIOS PHARMACEUTICALS INC. SELLS 2.5 MILLION SHARES OF COMMON STOCK IN INITIAL PUBLIC OFFERING
TELIOS ANNOUNCES SECOND QUARTER 1992 RESULTS
TELIOS ANNOUNCES THIRD QUARTER 1992 RESULTS
LEADING RESEARCHERS REPORT THAT TP-9201 PREVENTS BLOOD CLOTTING WITHOUT INCREASING BLEEDING TIME
TELIOS PHARMACEUTICALS SIGNS AN AGREEMENT WITH LILLY TO DEVELOP NOVEL OSTEOPOROSIS THERAPEUTICS
TELIOS ANNOUNCES FOURTH QUARTER 1992 RESULTS
TELIOS SUBMITS PMA FOR TELIO-DERM(R) WOUND HEALING AGENT
TELIOS ANNOUNCES FIRST QUARTER 1993 RESULTS
Integra LifeSciences Receives Nearly $600,000 in Grants
Serologicals Corporation CEO David A. Dodd Elected Vice Chairman of Georgia Biomedical Partnership.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters